Evaluation of patients with a pathological accumulation of fluid to determine whether pancreatic inflammation, pancreatic fistula, or esophageal rupture may be contributing
Aiding in the diagnosis of pancreatitis
Enzymatic Colorimetric
Amylase Frac, Body Fluid
Amylase, Macro, Body Fluids
Body Fluid
For pancreatic cyst fluid specimens, order AMLPC / Amylase, Pancreatic Cyst Fluid. Testing will be changed to AMLPC if this test is ordered on that specimen type.
1. Date and time of collection are required.
2. Specimen source is required.
Question ID | Description | Answers |
---|---|---|
FLD21 | Fluid Type, Amylase |
Specimen Type: Body fluid
Preferred Source:
-Peritoneal fluid (peritoneal, abdominal, ascites, paracentesis)
-Pleural fluid (pleural, chest, thoracentesis)
-Drain fluid (drainage, Jackson Pratt [JP] drain)
-Pericardial fluid
Acceptable Source: Write in source name with source location (if appropriate)
Collection Container/Tube: Sterile container
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Centrifuge to remove any cellular material and transfer into a plastic vial.
2. Indicate the specimen source and source location on label.
If not ordering electronically, complete, print, and send a Gastroenterology and Hepatology Test Request (T728) with the specimen.
0.5 mL
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Anticoagulant or additive, breast milk, nasal secretions, gastric secretions, bronchoalveolar lavage (BAL or bronchial washings), feces, colostomy/ ostomy, saliva, sputum, urine, vitreous fluid, or pancreatic cyst | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Body Fluid | Refrigerated (preferred) | 7 days | |
Frozen | 30 days | ||
Ambient | 24 hours |
Evaluation of patients with a pathological accumulation of fluid to determine whether pancreatic inflammation, pancreatic fistula, or esophageal rupture may be contributing
Aiding in the diagnosis of pancreatitis
Pleural fluid:
Amylase-rich pleural effusions are commonly associated with pancreatitis, esophageal rupture, malignancy, pneumonia, and liver cirrhosis.(1) Pleural fluid amylase measurement is not routinely indicated though may help to narrow the differential due to these causes. Results should be interpreted in conjunction with serum measurement usually as a ratio of pleural fluid to serum amylase. The ratio of pleural fluid to serum amylase in effusions caused by pancreatic disease is much higher (mean + or - SD = 18 + or - 6.3) versus non-pancreatic disease (4.8 + or - 1.3) (P = 0.003).(2) Isoform analysis revealed that pancreatic amylase is diagnostic of pancreatitis-related pleural effusions, whereas salivary amylase isoforms are more often associated with esophageal rupture and malignancy.(3)
Peritoneal fluid:
The digestive enzymes amylase and lipase can be measured in the identification of pancreatic fluid in the peritoneal cavity. Concentrations are expected to be elevated and at least several-fold times higher in fluid of pancreatic origin compared to simultaneous concentrations in serum.(4) In contrast, amylase concentration in ascites of non-pancreatic origin was approximately half the plasma value.(5)
Drain fluid:
Amylase might be measured in a drain fluid to aid in the identification of internal pancreatic fistulas due to chronic pancreatitis or formation of a fistula after surgery.(6,7) Comparison to serum concentrations is recommended with elevations several-fold higher than blood being suggestive of the presence of pancreatic fluid in the drained cavity.
An interpretive report will be provided
Peritoneal and drain fluid amylase activity in non-pancreatic peritoneal fluid is often less than or equal to the serum amylase activity. Ascites associated with pancreatitis typically has amylase activity at least 5-fold greater than serum.(1)
Normal pleural fluid amylase activity is typically less than the upper limit of normal serum amylase and has a ratio of pleural fluid amylase to serum amylase ratio less than 1.0.(3)
All Other Fluids: Body fluid amylase activity may become elevated due to the presence of pancreatitis, esophageal rupture, or amylase producing neoplasms. Results should be interpreted in conjunction with serum amylase and other clinical findings.
In very rare cases, gammopathy, in particular type IgM (Waldenstrom macroglobulinemia), may cause unreliable results.
Icodextrin-based drugs may lead to decreased amylase results.
1. Burgess LJ. Biochemical analysis of pleural, peritoneal and pericardial effusions. Clin Chim Acta. 2004;343:61-84
2. Joseph J, Viney S, Beck P, Strange C, Sahn SA, Basran GS. A prospective study of amylase-rich pleural effusions with special reference to amylase isoenzyme analysis. Chest. 1992;102:1455-1459
3. Sahn SA. Getting the most from pleural fluid analysis. Respirology. 2012;17:270-277
4. Robert JH, Meyer P, Rohner A. Can serum and peritoneal amylase and lipase determinations help in the early prognosis of acute pancreatitis? Ann Surg. 1986;203:163-168
5. Runyon BA. Amylase levels in ascitic fluid. J Clin Gastroenterol. 1987;9(2):172-174
6. Lipsett PA, Cameron JL. Internal pancreatic fistula. Am J Surg. 1992;163(2):216-220
7. Kaman L, Behera A, Singh R, Katariya RN. Internal pancreatic fistulas with pancreatic ascites and pancreatic pleural effusions: recognition and management. ANZ J Surg. 2001;71(4):221-225
8. Nandakumar V, Dolan C, Baumann NA, Block DR. Effect of pH on the quantification of body fluid analytes for clinical diagnostic testing. Am J Clin Path. 2019;152(S1):S10-S11
The liquid Roche amylase method is an enzymatic colorimetric test using 4,6-ethyliden (G7)-p-nitrophenol (G1)-alpha, D-maltoheptaoside (ethylidene-G7PNP) as a substrate. Human salivary and pancreatic amylases convert the substrate at approximately the same rate. The alpha-amylase cleaves the substrate into G2, G3, G4 PNP fragments. The G2 and G3 and G4 PNP fragments are further hydrolyzed by an alpha-glucosidase to yield p-nitrophenol and glucose. The rate of increase in absorbance at 415 nm (measuring the increase in p-nitrophenol) is proportional to amylase activity.(Package insert: Roche AMYL reagent. Roche Diagnostic Corp; V12.0, 02/2022)
Monday through Sunday
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
82150
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
AMBF | Amylase, BF | 1795-4 |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
AMBFL | Amylase, BF | 1795-4 |
FLD21 | Fluid Type, Amylase | 14725-6 |